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At the time of its early discovery and characterization, ﬁbro-
blast growth factor 23 (FGF23) was identiﬁed as a hormonal
substance produced by bone cells (osteoblast/osteocytes)mainly
devoted to controlling phosphorus balance by directly reducing
phosphate reabsorption in the proximal renal tubule and in-
directly decreasing phosphorus intestinal absorption, through
a reduced bioavailability of the most active vitamin D metabol-
ite (calcitriol) [1–3]. These characteristics formerly made this
new hormone the object of interest mainly in the endocrino-
logical ﬁeld encompassing some acquired or genetically trans-
mitted hypophosphatemic syndromes, such as tumor-induced
(TIO), X-linked, autosomal dominant and recessive
hypophosphatemic rickets/osteomalacia (XLHR/ADHR/ARHR)
syndromes which have been demonstrated to be directly or in-
directly linked to some disturbances associated with FGF23
and other strictly related phosphaturic substances (PHEX,
DMP-1, MEPE). However, many subsequent experimental
and observational studies reported on increased FGF23 con-
centrations from the very early stages of chronic kidney
disease (CKD) and provided data suggesting that high FGF23
levels might represent an independent risk factor for both
global and/or cardiovascular morbidity/mortality [4–6], not
only in CKD patients but also in the general population [7].
However, the presence of many potential confounders and
contradictions soon became evident, preventing a clear interpret-
ation of the results of this bulk of published studies, with many
questions still remaining unanswered.
An important unanswered question concerns whether the in-
creased circulating levels of FGF23 (the hormonal component)
or some disturbance in its tissue expression and/or signaling
(the autocrine/paracrine or ‘local’ component) can be implicated
in the putative pathogenic link with cardiovascular morbidity.
Anyway, for both these putative conditions a series of crit-
ical points arise.
The increase of FGF23 levels in CKD probably represents a
homeostatic response directed to maintain a neutral phosphorus
balance, given the trend toward a reduced renal excretion, in
spite of an almost unchanged intestinal phosphorus absorption
in the course of CKD. It is worth underlining that the trend to
phosphorus retention in CKD is secondary not only to the
reduced glomerular ﬁltration volume, but probably also to the
tubular resistance to the phosphaturic action of FGF23, second-
ary to the progressive reduction of α-Klotho, which plays a basic
role in increasing the afﬁnity of FGF23 receptors.
Since both phosphorus retention and α-Klotho reduction
may independently play a pathogenic role in CV morbidity, it is
not easy to understand how much of this putative pathogenic
role should be ascribed to the FGF23 per se or to the above
quoted primary conditions causative for the FGF23 increase [8].
In particular, the reduced tissue α-Klotho availability has recently
gained much credit as a primary CV pathogenic factor [9, 10].
On the other hand, it cannot be excluded that extremely
high FGF23 levels may cease to represent a compensatory phe-
nomenon, displaying a direct pathogenic ‘off-target’ effect,
possibly through a non-speciﬁc occupation of FGF receptors
even in the absence of Klotho, given the exceedingly high con-
centrations occurring at the latest stages of CKD [6, 11, 12].
However, even if this is the case, uncertainties would still
remain on what the FGF23 level threshold is above which the
pathogenic role starts to be evident. In fact, looking at the
results of the study by Faul et al. [6], the FGF23 levels asso-
ciated with a pathogenic effect on cardiac mass in the experi-
mental models were manifoldly higher than those found in the
clinical observational section of the same study.
Overall, when the effects of FGF23 have been blocked with
monoclonal anti-FGF23 antibodies in an experimental animal
model of CKD, even if hyperparathyroidism was better con-
trolled, the net result was a net increase in animal mortality
[13], these data cast some doubt on the putative direct patho-
genic effect of FGF23.
However, a basic limitation in making clear any message on
the role of the circulating levels of FGF23 is represented by the
lack of a widely accepted gold-standard method for dosing this
hormone. In fact, circulating FGF23 is present as both intact-
© The Author 2014. Published by Oxford University Press
on behalf of ERA-EDTA. All rights reserved.
1447
 at Biblioteca IRCCS O
spedale M
aggiore - M
ilano on January 20, 2016
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
FGF23 and C-terminal fragment(s). There are available assays
for measuring all these forms, however most of the published
studies have limited themselves to use only one of these
methods. Just citing the most relevant limitations related to
this point, it is worth stressing that it is well accepted that the
full activity of FGF23 is held by the intact molecule, while con-
ﬂicting results have been reported on the possible activity of
the C-terminal fragment(s), since some authors reported on a
possible maintained activity [14] while others suggested a po-
tential antagonist effect of C-terminal fragment(s) on the main
activity of the full moiety [15]. Second, since there are multiple
available assays for the measurement of the intact molecule, it
has been clearly shown that there is limited comparability
among the different available assays measuring either the intact
or the C-terminal molecule [16, 17]. Furthermore, critical pre-
analytical problems have been reported, with a trend to an in-
crease and a reduction of the C-terminal and intact molecule,
respectively, when the sample is maintained at room tempera-
ture for >30 min in the absence of protease inhibitors [18].
To complicate the interpretation of FGF23/Klotho system,
recent studies suggest that quite similar analytical problems
might be encountered for the assessment of circulating levels
of Klotho too [19, 20].
It is well recognized that vascular calciﬁcation in CKD pa-
tients is an active and cell-regulated process driven by a great
number of putative causal factors inducing local phenotypic
transdifferentiation of vascular smooth muscle cells towards an
osteochondrogenic phenotype [21].
Recent studies suggested that FGF23 could also play some
role in the CV disease of CKD patients, showing that FGF23
can be expressed both in cardiomyocytes and in the calciﬁed
aorta wall, suggesting that in addition, and probably independ-
ently of the circulating levels of FGF23, the tissue expression of
this protein might play a potential direct pathogenic role [22,
23]. In this issue of the Nephrology, Dialysis and Transplant-
ation journal, van Venrooij et al. [24] report on the expression
of FGF23 in the coronary arteries of the explanted hearts in
more than half of the 50 patients who received a heart trans-
plantation. The renal function was lower in patients whose
coronary arteries expressed FGF23 than in patients with no
FGF23 coronary expression, though part of the positive pa-
tients had completely normal renal function. Another import-
ant ﬁnding of this study was that FGF23 protein was co-
expressed with its main receptors (FGFR-1 and FGFR3) and
its co-receptor Klotho. Furthermore, the degree of FGF23 ex-
pression was positively correlated with coronary calcium score
and with the expression of a speciﬁc osteocyte protein
(DMP1). Interestingly, the expression of FGF23 was mainly
evident in inﬁltrating macrophage cells. Other authors had re-
cently reported on an association between circulating FGF23
levels and markers of inﬂammation in CKD patients [25], the
potential links between FGF23 and inﬂammation being mani-
fold (Figure 1). These hypothetical links are mainly pertinent
to systemic inﬂammatory conditions. However, at variance
with these previous studies, the results from van Venrooij
et al. seem to suggest that FGF23 expression in the coronary
wall is mainly associated with local more than systemic inﬂam-
mation, given that the authors did not ﬁnd any difference in
systemic inﬂammatory markers between patients with and
without FGF23 expression in the coronary arteries. These
results ﬁt well with those from a recent study which demon-
strated that the accumulation of macrophage foam cells in es-
tablished atherosclerotic lesions is mainly derived from ‘in
loco’ macrophage proliferation within the lesion and not from
monocyte recruitment from circulation [26].
However, these results raise new questions which are far
from being answered. The ﬁrst point to be clariﬁed regards
whether the increased, either circulating or local, levels of
FGF32 are a primary or secondary event in relationship to the
vascular inﬂammation and/or to the calciﬁcation process. The
second point to be demonstrated is whether increased FGF23
plays a promoting or a protective role in the vascular disease.
The third point to be clariﬁed is whether the FGF23, secreted
by the inﬁltrating macrophages, actively contributes to these
F IGURE 1 : Potential relationships between FGF23 and inﬂammation: OB, osteoblast; OC, osteocyte.
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roles or if it simply represents a marker of a trans-differenti-
ation process of macrophage itself toward an osteochondro-
genic cell. Furthermore, a point to be addressed concerns
whether this extra-skeletal production of FGF23 can contrib-
ute to its increased circulating levels in the same way of other
pathological conditions (e.g. tumor-induced osteomalacic syn-
dromes). Finally, it is not completely clear whether the poten-
tial positive or negative effects of FGF23 on the vascular wall
are mediated or not by Klotho.
Overall, in addition to all the uncertainties listed in the previ-
ous paragraphs, it still remains to be ascertained which of the
cardiovascular pathological conditions are mainly associated
with higher FGF23 levels. In fact, while some studies reported
an independent association between circulating FGF23 concen-
tration and the severity and extent of coronary artery stenosis or
with the progression of coronary calciﬁcations [27, 28], other
recent data seem to suggest a prevalent association of FGF23
levels with left ventricular mass and heart failure but not with
ischaemic heart disease [29, 30].
In conclusion, the study from van Venrooij et al. sheds
further light on this ever more complicated issue, though at
the same time it also raises new unanswered questions.
As for any experimental study, we look forward to seeing
replication of these unexpected and exciting results in further
studies, and, if conﬁrmed, future research could further clarify
this increasingly complex issue.
Any new piece to be added in this tangled puzzle will be
welcome.
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